The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S… read more
ALPS Funds
ETF
Equity
- years
104 holdings
$36.38
Price-0.86%
-$0.32
$80.189m
Small
$6.027k
Avg Volume$114.954m
$37.69
NAV0.50%
Expense Ratio3.22%
Yield$1.17
Dividend